Literature DB >> 21586282

Chronic glucokinase activation reduces glycaemia and improves glucose tolerance in high-fat diet fed mice.

Maria Sörhede Winzell1, Matthew Coghlan, Brendan Leighton, Georgia Frangioudakis, David M Smith, Leonard H Storlien, Bo Ahrén.   

Abstract

Glucokinase (GK) plays a key role in maintaining glucose homeostasis by promoting insulin secretion from pancreatic beta cells and increasing hepatic glucose uptake. Here we investigate the effects of acute and chronic GK activation on glucose tolerance and insulin secretion in mice with diet-induced insulin resistance. In the acute study, a small molecule GK activator (GKA71) was administered to mice fed a high-fat diet for 8 weeks. In the long-term study, GKA71 was provided in the diet for 4 weeks to high-fat diet-fed mice. Glucose tolerance was measured after intravenous glucose administration, and insulin secretion was measured both in vivo and in vitro. Acute GK activation efficiently improved glucose tolerance in association with increased insulin secretion after intravenous glucose both in control and high-fat fed mice. Chronic GK activation significantly reduced basal plasma glucose and insulin, and improved glucose tolerance despite reduced insulin secretion after intravenous glucose, suggesting improved insulin sensitivity. Isolated islets from chronically GKA71-treated mice displayed augmented insulin secretion at 8.3 mmol/l glucose, without affecting glucose oxidation. High-fat diet fed mice had reduced glycogen and increased triglyceride in liver compared to control mice, and these parameters were not altered by long-term GK activation. We conclude that GK activation in high-fat diet-fed mice potently reduces glycaemia and improves glucose tolerance, with combined effect both to stimulate insulin secretion from islets and improve insulin sensitivity.
Copyright © 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21586282     DOI: 10.1016/j.ejphar.2011.05.009

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  12 in total

1.  Kaempferol ameliorates hyperglycemia through suppressing hepatic gluconeogenesis and enhancing hepatic insulin sensitivity in diet-induced obese mice.

Authors:  Hana Alkhalidy; Will Moore; Aihua Wang; Jing Luo; Ryan P McMillan; Yao Wang; Wei Zhen; Matthew W Hulver; Dongmin Liu
Journal:  J Nutr Biochem       Date:  2018-05-01       Impact factor: 6.048

2.  S 50131 and S 51434, two novel small molecule glucokinase activators, lack chronic efficacy despite potent acute antihyperglycaemic activity in diabetic mice.

Authors:  Frédéric De Ceuninck; Catherine Kargar; Yves Charton; Solo Goldstein; Françoise Perron-Sierra; Catherine Ilic; Audrey Caliez; Jean-Olivier Rolin; Marjorie Sadlo; Elizabeth Harley; Cédric Vinson; Alain Ktorza
Journal:  Br J Pharmacol       Date:  2013-07       Impact factor: 8.739

3.  Hepatic glucose uptake and disposition during short-term high-fat vs. high-fructose feeding.

Authors:  Katie C Coate; Guillaume Kraft; Mary Courtney Moore; Marta S Smith; Christopher Ramnanan; Jose M Irimia; Peter J Roach; Ben Farmer; Doss W Neal; Phil Williams; Alan D Cherrington
Journal:  Am J Physiol Endocrinol Metab       Date:  2014-05-27       Impact factor: 4.310

4.  Knockout of SOD1 alters murine hepatic glycolysis, gluconeogenesis, and lipogenesis.

Authors:  Li Wang; Zongyong Jiang; Xin Gen Lei
Journal:  Free Radic Biol Med       Date:  2012-08-25       Impact factor: 7.376

5.  Hepatic ATGL knockdown uncouples glucose intolerance from liver TAG accumulation.

Authors:  Kuok Teong Ong; Mara T Mashek; So Young Bu; Douglas G Mashek
Journal:  FASEB J       Date:  2012-09-19       Impact factor: 5.191

6.  Dietary selenium deficiency partially rescues type 2 diabetes-like phenotypes of glutathione peroxidase-1-overexpressing male mice.

Authors:  Xi Yan; Matthew P Pepper; Marko Z Vatamaniuk; Carol A Roneker; Li Li; Xin Gen Lei
Journal:  J Nutr       Date:  2012-09-26       Impact factor: 4.798

7.  Chronic glucokinase activator treatment at clinically translatable exposures gives durable glucose lowering in two animal models of type 2 diabetes.

Authors:  D J Baker; G P Wilkinson; A M Atkinson; H B Jones; M Coghlan; A D Charles; B Leighton
Journal:  Br J Pharmacol       Date:  2014-04       Impact factor: 8.739

8.  Preclinical PK/PD modeling and human efficacious dose projection for a glucokinase activator in the treatment of diabetes.

Authors:  Michael G Zager; Kirk Kozminski; Bernadette Pascual; Kathleen M Ogilvie; Shaoxian Sun
Journal:  J Pharmacokinet Pharmacodyn       Date:  2014-02-28       Impact factor: 2.745

9.  Small molecule glucokinase activators disturb lipid homeostasis and induce fatty liver in rodents: a warning for therapeutic applications in humans.

Authors:  Frédéric De Ceuninck; Catherine Kargar; Catherine Ilic; Audrey Caliez; Jean-Olivier Rolin; Thierry Umbdenstock; Cédric Vinson; Murielle Combettes; Brant de Fanti; Elizabeth Harley; Marjorie Sadlo; Anne-Laure Lefèvre; Olivier Broux; Michel Wierzbicki; Jean-Marie Fourquez; Françoise Perron-Sierra; András Kotschy; Alain Ktorza
Journal:  Br J Pharmacol       Date:  2013-01       Impact factor: 8.739

10.  Qizhi Jiangtang Jiaonang Improves Insulin Signaling and Reduces Inflammatory Cytokine Secretion and Reactive Oxygen Species Formation in Insulin Resistant HepG2 Cells.

Authors:  Xiao-Tian Zhang; Chun-Jiang Yu; Jian-Wei Liu; Yan-Ping Zhang; Chao Zhang; Chen-Xue Song; Jing-Shu Xie; Jing-Ying Sai; Jing-Tong Zheng; Fang Wang
Journal:  Evid Based Complement Alternat Med       Date:  2015-05-05       Impact factor: 2.629

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.